Concentrix in the news

Concentrix Corp's stock price dropped 4.0% to $24.84, trading significantly below its estimated fair value of $58.19, despite warnings of a possible value trap due to unprofitability and insider selling.

Concentrix VP Paula Kennedy Garcia received a Silver Stevie Award for Female Executive of the Year in EMEA due to her leadership in driving regional growth and championing women's initiatives.

A law firm is investigating Concentrix after the company twice lowered its financial outlook and disclosed significant goodwill impairments, leading to substantial stock drops.

Concentrix shows a significant valuation disconnect, with a low P/E despite strong operational cash flow and a substantial non-cash goodwill impairment impacting GAAP net loss.

Concentrix reported a net loss and weak guidance, causing a significant stock price decline, though many investors still see it as undervalued despite concerns over debt and integration.

Concentrix's stock dropped due to a goodwill impairment and softer revenue outlook, despite exceeding profit guidance and over half its revenue now coming from AI.

Concentrix acquired PK, a customer experience engineering firm, to accelerate clients' digital transformation and expand its digital CX capabilities.

Concentrix announced its Q3 2026 financial results, including $2.45 billion in revenue, a GAAP operating loss primarily due to a goodwill impairment, but positive non-GAAP operating income growth, record operating cash flow, and a significant portion of revenue from new, AI-driven business.

Concentrix Corp's shares dropped 7.8% on October 2, 2026, leading to a valuation that is considered undervalued by GF Value, but concerns exist due to unprofitability and significant insider selling.

Concentrix's Q3 results show a significant non-cash goodwill impairment leading to a net loss, but positive non-GAAP profitability driven by over half of its revenue coming from AI-related services, with future projections aiming for AI-led growth.

United Therapeutics, Moderna, Jabil, and Concentrix experienced significant stock movements yesterday following company-specific news.

BofA Securities cut its price target for Concentrix Corp. to $29.00 from $30.00 due to macroeconomic headwinds, despite the company exceeding profitability guidance and raising its dividend.

Shares of Concentrix, Huron, and TaskUs jumped following Accenture's positive earnings and outlook, which eased fears about AI's impact on consulting and outsourcing.

Concentrix missed Q3 2026 revenue expectations with a 1.2% year-on-year sales decline to $2.45 billion, although non-GAAP profit per share beat estimates.

Concentrix reported a substantial net loss in Q3 2026 due to a $1.5 billion non-cash goodwill impairment and declining revenue, yet its stock initially jumped before cooling down.

The company reported Q3 revenue slightly below guidance but exceeded expectations for non-GAAP operating income and EPS, reduced debt, and provided optimistic forecasts for new business and future earnings.

Concentrix reported mixed Q3 results with an earnings beat but a sales miss, leading to a sharp drop in its stock price due to weak guidance.

Concentrix reported a Q3 revenue miss, a $1B goodwill impairment, and lowered future guidance, causing a significant share price drop.

Concentrix exceeded Q3 profitability guidance with strong free cash flow, debt reduction, and significant new business and AI-driven sales momentum, despite a slight revenue dip.

Concentrix's stock jumped despite a significant net loss and declining revenue, largely due to a non-cash goodwill impairment charge, while adjusted free cash flow and operating margin improved.